Infrared Headgear Shows Promise for Treating Brain Disorders
Researchers in France are exploring a novel approach to treating neurodegenerative diseases like Alzheimer’s and Parkinson’s using infrared light delivered via a specialized headset. This innovative therapeutic strategy, currently under development at the CEA (French Alternative Energies and Atomic Energy Commission) in Grenoble, represents a shift towards utilizing physics in the treatment of brain disorders, building on its established role in medical diagnostics.
The research is rooted in the idea that physics can revolutionize therapeutics in the 21st century, following its impact on medical imaging in the 20th. The team’s approach addresses a challenge in the field, as traditional chemical interventions have faced difficulties in effectively addressing these complex conditions.
Alzheimer’s disease, the most prevalent neurodegenerative disorder, affects nearly 900,000 people in France and is expected to impact 1.3 million individuals by 2020 as the population ages, according to data from the Institut Pasteur. The disease, which is rare before age 65, affects 15% of those aged 80 and older.
Early symptoms of Alzheimer’s typically involve short-term memory loss, progressing to difficulties with executive functions – such as using familiar objects or completing routine tasks – and disorientation in time and space, including getting lost or losing track of the date. As the disease advances, individuals experience a gradual decline in mental abilities and independence, accompanied by language, writing, movement, behavioral, mood (anxiety, depression, irritability), and sleep disturbances. This progression can span several years, varying in speed from person to person.
Researchers have identified two key factors in the development of Alzheimer’s: the beta-amyloid peptide and the tau protein. These elements contribute to the slow degeneration of neurons, beginning in regions like the hippocampus – crucial for short-term memory – and eventually spreading throughout the brain.
Parkinson’s disease, which affects approximately 200,000 people in France, is likewise a focus of this research. Recent advancements in understanding and treating both Parkinson’s and Alzheimer’s were discussed at the 14th University of Summer on Ethics and Neuro-evolutionary Diseases held in Bordeaux from September 24-26, 2023, as reported by Sud Ouest. The event brought together healthcare professionals, researchers, and families affected by these diseases.
“Research is progressing,” noted Dr. Véronique Avérous, director of Erena and head of palliative medicine at the CHU of Bordeaux. “However, science does not disregard the perspective of patients and their families, which compels us to preserve moral and empathetic values.” Professor Bernard Bioulac, a renowned neurobiologist from the University of Bordeaux, presented the latest findings on Parkinson’s disease during the conference.
The development of new treatments for these debilitating conditions remains a critical public health priority, given the increasing prevalence of neurodegenerative diseases with aging populations. The innovative approach using infrared light offers a potential new avenue for therapeutic intervention.
